Rock Creek Pharmaceuticals Inc  

(Public, OTCMKTS:RCPI)   Watch this stock  
Find more results for NASDAQ:STSI
0.000 (0.00%)
Feb 8 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.61 - 4.62
Open     -
Vol / Avg. 0.00/32,074.00
Mkt cap 7.98M
P/E     -
Div/yield     -
EPS -1.60
Shares 10.87M
Beta 1.39
Inst. own 9%

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -67.94% -333.34%
Return on average equity - -
Employees 10 -
CDP Score - -


2040 Whitfield Avenue, Suite 300
United States - Map
+1-804-5271970 (Phone)
+1-302-6365454 (Fax)

Website links


Rock Creek Pharmaceuticals, Inc. is a pharmaceutical development company. The Company is focused on the discovery, development, and commercialization of therapies for chronic inflammatory disease, neurologic disorders, and behavioral health utilizing its compounds. Its development activities are focused on its lead compound, anatabine citrate. Anatabine citrate is a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics, with a mechanism of action distinct from other anti-inflammatory drugs available, such as biologics, steroids and non-steroidal anti-inflammatories. Its lead compounds have shown preclinical in vitro and in vivo ability to modulate the expression of specific inflammatory molecules considered relevant to many chronic inflammatory disease states.

Officers and directors

Michael John Mullan Ph.D., M.D. Chairman of the Board, Office of President, Chief Executive Officer
Age: 58
William L. McMahon Interim Chief Financial Officer, Treasurer
Age: 62
Theodore Jenkins Secretary, Vice President - Corporate Strategy & Development
Lee M. Canaan Independent Director
Age: 59
Sunitha Chundru Samuel Independent Director
Age: 38
Robert W. Scannell Independent Director
Age: 57
Scott P. Sensenbrenner Independent Director
Age: 45